← Back

Addex Therapeutics Ltd

Addex Therapeutics Ltd is a Swiss company that discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders. Its research focuses on G-protein coupled receptors and enzymes. Lead programs include Dipraglurant, in phase 1 trials for post-stroke/TBI recovery and Parkinson's disease levodopa-induced dyskinesia, ADX71149, in phase 1 for an undisclosed indication, and GABAB PAM for pain, anxiety, addiction, chronic cough, and overactive bladder. The company has license and collaboration agreements with Janssen Pharmaceuticals Inc. for mGlu2 PAM compounds and with Indivior PLC for GABAB PAM compounds. Formerly Addex Pharmaceuticals Ltd, it was founded in 2002 and is based in Geneva, Switzerland.

Price · split & dividend adjusted
News & notes moving ADXN
Biotech & Genomic Medicine▲

Addex Research Shows MGlu7 Modulator Alters Sleep And Stress In Preclinical Study

Addex Therapeutics announced new preclinical research showing that its compound ADX71743, a selective negative allosteric modulator of mGlu7, significantly influences sleep-wake cycles and stress-related neurochemistry in animal models. The study, published in the International Journal of Neuropsychopharmacology, found that ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats, and altered stress-induced changes in neurotransmitters such as glutamate, GABA and monoamines across multiple brain regions. CEO Tim Dyer said the findings add important evidence supporting the therapeutic potential of targeting these receptors, and strengthen the rationale for Neurosterix's ongoing development of the mGlu7 program. ADX71743, discovered by Addex, has served as a prototype molecule in numerous publications exploring mGlu7's role in anxiety, stress, sleep, fear memory, and visceral pain. The program is now being advanced by Neurosterix, a neuroscience company launched by Addex and Perceptive Advisors in 2024.
ADXN.SW ▲
Biotech & Genomic Medicine
RTTNews·72dRead more →
ADXN

Addex shareholders approve all board proposals at 2026 AGM

Addex Therapeutics shareholders approved all proposals of the Board of Directors at the company's 2026 Annual General Meeting, with votes representing 29.35% of outstanding capital. The approved items included the 2025 annual report, consolidated and annual financial statements, appropriation of results, and the compensation report in a consultative vote. Shareholders also re-elected all board members, including Dr. Vincent Lawton as chairman, and approved amendments to the Articles of Association to increase the capital band and conditional share capital. BDO SA was re-elected as auditor and Robert P. Briner as independent voting rights representative until the 2027 AGM.
ADXN.SW
GlobeNewswire·81dRead more →
Biotech & Genomic Medicine▼2

Addex Records Wider Net Loss Of $1.7 Mln; Advances NTX-253 In Phase 1 For Schizophrenia

Addex Therapeutics reported a first-quarter net loss of CHF 1.71 million, wider than the CHF 1.47 million loss a year ago, as revenue fell sharply. Revenue dropped to CHF 8,000 from CHF 71,000 in the prior-year quarter, while research and development expenses declined to CHF 0.04 million from CHF 0.16 million. Cash and cash equivalents stood at CHF 0.93 million as of March 31, 2026. The company is advancing its M4 positive allosteric modulator NTX-253 through its spun-out entity Neurosterix, with a Phase 1 trial for schizophrenia expected to complete in July. Addex is also developing a GABAB PAM for chronic cough in preclinical studies.
ADXN.SW ▼
Biotech & Genomic Medicine
RTTNews·86dRead more →
© 2026 MarketDXAsset